Menu
Search
|

Menu

Close
X

Sichuan Languang Development Co Ltd 600466.SS (Shanghai Stock Exchange)

5.74 CNY
-- (--)
As of Jul 19
chart
Previous Close 5.74
Open --
Volume --
3m Avg Volume 19,936,902
Today’s High --
Today’s Low --
52 Week High 9.59
52 Week Low 5.61
Shares Outstanding (mil) 2,134.30
Market Capitalization (mil) 18,995.24
Forward P/E 16.77
Dividend (Yield %) 0.10 ( 1.12 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.14 Mean rating from 7 analysts

KEY STATS

Revenue (mm, CNY)
FY18
3,326
FY17
24,553
FY16
21,329
FY15
17,598
EPS (CNY)
FY18
0.101
FY17
0.399
FY16
0.302
FY15
0.318
*Note: Units in Millions of Renminbi
**Note: Units in Renminbi

KEY RATIOS

Price to Earnings (TTM)
vs sector
16.77
32.76
Price to Sales (TTM)
vs sector
0.83
5.73
Price to Book (MRQ)
vs sector
1.75
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
308.87
16.84
LT Debt to Equity (MRQ)
vs sector
232.47
12.51
Return on Investment (TTM)
vs sector
3.99
14.61
Return on Equity (TTM)
vs sector
11.67
16.34

EXECUTIVE LEADERSHIP

Keng Yang
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Qiaolong Zhang
President, Vice Chairman of the Board, Since 2018
Salary: --
Bonus: --
Junming Ou
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Zhenggang Lu
Senior Vice President, Director, Since 2017
Salary: --
Bonus: --
Gaofei Li
Vice President, Secretary of the Board, Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

No.9
Xixin Avenue, (West Zone) Hi-tec
CHENGDU   SIC   611731

Phone: +8628.87826466

SICHUAN LANGUANG DEVELOPMENT CO., LTD. mainly operates business through real estate development and operation, modern service industry, 3 dimension (3D) bio-printing and medical segment. The Real Sstate Development & Operation segment has more than 100 development projects in nearly 20 cities in China. The Modern Service Industry segment provides property service based modern services through the subsidiary, Sichuan JUSTBON Asset Management Group Co., Ltd. The 3D Bio-printing segment is involved in the application of 3D bio-printing technology through the subsidiary, Sichuan Revotek Bio-technology Co., Ltd. The Medical segment is involved in the research and development, production and sales of medicine and medical instruments through the subsidiary, Chengdu Dikang Pharmaceutical Co., Ltd.

SPONSORED STORIES